PremiumThe FlySandoz files antitrust litigation against Amgen regarding Enbrel Sandoz price target lowered to CHF 46.50 from CHF 50 at Barclays Sandoz price target lowered to CHF 46 from CHF 48 at JPMorgan PremiumRatingsSandoz Group Ltd: Strong Financial Performance and Resilient Outlook Justify Buy Rating Sandoz launches Pyzchiva in the U.S. Sandoz price target raised to CHF 41 from CHF 35 at Morgan Stanley PremiumThe FlyIntra-Cellular price target raised to $118 from $100 at BofA Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement 
